How to buy Neoleukin Therapeutics stock (NLTX)

Neoleukin Therapeutics is a biotechnology business based in the US. Neoleukin Therapeutics shares (NLTX) are listed on the NASDAQ and all prices are listed in US Dollars. Neoleukin Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Neoleukin Therapeutics stock

Buy Neoleukin Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Neoleukin Therapeutics stock price (NASDAQ: NLTX)

Use our graph to track the performance of NLTX stocks over time.

Neoleukin Therapeutics shares at a glance

• Key figures

Information last updated 2024-02-11.

52-week range	$0.00 - $0.00
50-day moving average more info button	$13.83
200-day moving average more info button	$14.98
Wall St. target price	$1.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-12.28

Is it a good time to buy Neoleukin Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neoleukin Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-18.71%
Return on equity TTM	-37.88%
Profit margin	0%
Book value	$34.18
Market Capitalization more info button	$8.2 million

TTM: trailing 12 months

Neoleukin Therapeutics share dividends

We're not expecting Neoleukin Therapeutics to pay a dividend over the next 12 months.

Have Neoleukin Therapeutics's shares ever split?

Neoleukin Therapeutics's shares were split on a 1:4 basis on 18 December 2023 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neoleukin Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Neoleukin Therapeutics shares which in turn could have impacted Neoleukin Therapeutics's share price.

Neoleukin Therapeutics share price volatility

Over the last 12 months, Neoleukin Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neoleukin Therapeutics's is 1.102. This would suggest that Neoleukin Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Neoleukin Therapeutics overview

Neoleukin Therapeutics, Inc. , a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc.

Frequently asked questions

What percentage of Neoleukin Therapeutics is owned by insiders or institutions?
Currently 16.461% of Neoleukin Therapeutics shares are held by insiders and 45.589% by institutions. How many people work for Neoleukin Therapeutics?
Latest data suggests 7 work at Neoleukin Therapeutics. When does the fiscal year end for Neoleukin Therapeutics?
Neoleukin Therapeutics's fiscal year ends in December. Where is Neoleukin Therapeutics based?
Neoleukin Therapeutics's address is: 188 East Blaine Street, Seattle, WA, United States, 98102 What is Neoleukin Therapeutics's ISIN number?
Neoleukin Therapeutics's international securities identification number is: US64049K1043 What is Neoleukin Therapeutics's CUSIP number?
Neoleukin Therapeutics's Committee on Uniform Securities Identification Procedures number is: 64049K104